Citius Oncology, Inc.

CTOR
$0.70 (- $0.02 - 2.75%)
Last updated: 2026-06-10 20:12 UTC
CTOR Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS17331Y1091
CUSIP17331Y109
Market Price0.7
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.34
Market Cap$96.2M
Book Value0.45
Price to Book2.506
Beta2.99
52w High6.19
52w Low0.55
Next Earnings DateN/A

Citius Oncology, Inc. trades under ticker CTOR on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US17331Y1091, CUSIP 17331Y109.

About the Company
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Price History